Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model (Q43799201)

26 November 2017

Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model (English)

1 reference

26 November 2017

1 reference

1 reference

1 reference

Meena Sharma

1

1 reference

PubMed ID

22044461

26 November 2017

Marc R Blackman

series ordinal

2

1 reference

PubMed ID

22044461

26 November 2017

Mahesh C Sharma

series ordinal

3

1 reference

26 November 2017

25 October 2011

1 reference

Experimental and Molecular Pathology

26 November 2017

10

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

26 November 2017

92

1 reference

26 November 2017

1

1 reference

26 November 2017

175-184

1 reference

Tissue plasminogen activator in murine exocrine pancreas cancer: selective expression in ductal tumors and contribution to cancer progression.

26 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Identification of endothelial cell genes expressed in an in vitro model of angiogenesis: induction of ESM-1, (beta)ig-h3, and NrCAM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Polymeric nanoparticles for sustained down-regulation of annexin A2 inhibit prostate tumor growth.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Biomedicine. Clotting factors build blood vessels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Tissue-type plasminogen activator is upregulated in metastatic breast cancer cells exposed to insulin-like growth factor-I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Annexins in human breast cancer: Possible predictors of pathological response to neoadjuvant chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Tissue plasminogen activator is required for the growth, invasion, and angiogenesis of pancreatic tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Tissue plasminogen activator expression in meningiomas and glioblastomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Tissue-type plasminogen activator in plasma from breast cancer patients determined by enzyme-linked immunosorbent assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Annexin II: a novel mediator of cell surface plasmin generation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Urokinase-type plasminogen activator antigen and early relapse in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Annexin A2 is a molecular target for TM601, a peptide with tumor-targeting and anti-angiogenic effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Immunosensors for detection of Annexin II and MUC5AC for early diagnosis of lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Agents that bind annexin A2 suppress ocular neovascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

A truncated plasminogen activator inhibitor-1 protein induces and inhibits angiostatin (kringles 1-3), a plasminogen cleavage product

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Systemic fibrinolysis caused by tissue plasminogen activator-producing metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

The role of the coagulation system in tumour angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Annexin II represents metastatic potential in clear-cell renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Angiostatin induces and sustains dormancy of human primary tumors in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Tissue-type plasminogen activator as marker of functional steroid receptors in human breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Metastasis-associated protein S100A4 induces angiogenesis through interaction with Annexin II and accelerated plasmin formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: possible biochemical mechanism of angiostatin's action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Role of Annexin-II in GI cancers: interaction with gastrins/progastrins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Angiostatin receptor annexin II in vascular tumors including angiosarcoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Plasmin-induced migration of endothelial cells. A potential target for the anti-angiogenic action of angiostatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Angiostatin binds to tyrosine kinase substrate annexin II through the lysine-binding domain in endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Identification of molecular markers for the oncogenic differentiation of hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Anxa2 plays a critical role in enhanced invasiveness of the multidrug resistant human breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Expression of annexin II in conventional renal cell carcinoma is correlated with Fuhrman grade and clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2011.10.003

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YEXMP.2011.10.003

1 reference

26 November 2017

1 reference

PubMed ID

22044461